We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
IGENE Biotechnology Inc (CE) | USOTC:IGNE | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.000001 | 0.00 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
Date of Report: November 24, 2009
(Date of earliest event reported)
Maryland 000-15888 52-1230461 _________________ ________________ ___________________ (State or Other (Commission File (IRS Employer Jurisdiction Number) Identification No.) of Incorporation) 9110 Red Branch Road 21045 Columbia, Maryland _____________________ _______________ (Address of principal (Zip code) executive of offices) (410) 997-2599 ______________________________ |
(Registrant's telephone number
including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d- 2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e- 4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On November 24, 2009, the directors of IGENE Biotechnology, Inc. (the "Company") unanimously resolved to delete Section 11 of Article 1 of the Bylaws of the Company and replace it with: "Informal Action by Stockholders. Any action required or permitted to be taken at any meeting of stockholders may be taken without a meeting if a consent in writing setting forth such action is signed by the holders of the requisite number of shares as provided herein and who are entitled to vote thereon and such consent is filed with the records of stockholders' meetings."
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IGENE BIOTECHNOLOGY, INC.
December 1, 2009 By: /S/ STEPHEN F. HIU _______________________________ STEPHEN F. HIU President |
1 Year IGENE Biotechnology (CE) Chart |
1 Month IGENE Biotechnology (CE) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions